Clozapine maintenance therapy in schizophrenia

@article{Gaszner2004ClozapineMT,
  title={Clozapine maintenance therapy in schizophrenia},
  author={P{\'e}ter Gaszner and Zolt{\'a}n Makkos},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2004},
  volume={28},
  pages={465-469}
}
  • P. GasznerZ. Makkos
  • Published 1 May 2004
  • Psychology, Medicine
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry

Strong Treatment Response and High Maintenance Rates of Clozapine in Childhood-Onset Schizophrenia.

The overall findings indicate that very early-onset schizophrenic patients may be more responsive to clozapine, relative to other antipsychotics, in COS than in AOS.

Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses

The use of long-acting preparations of atypical antipsychotics, which provide consistent and sustained drug coverage, warrants further investigation for the successful long-term management of patients with schizophrenia.

Reduction in hospital stay of chronic schizophrenic patients after long-term clozapine treatment

It was showed that the number and length of hospitalizations are significantly decreased by long-term clozapine treatment and that this effect can positively affect the social outcome of schizophrenic patients.

Augmenting Clozapine Response in Treatment-Resistant Schizophrenia

The present chapter focuses on controlled evidence available to guide clinical decision making in the face of clozapine partial response, and underscores the need for substantially more work along these lines.

Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making

Past efficacy trials have strongly supported the position that SGAs are superior to FGAs in the treatment of schizophrenia and in side effect profile, and two large independent effectiveness trials have offered a strong challenge to these claims.

Antipsychotic treatment and adherence in schizophrenia

This chapter provides a comprehensive review of adherence with antipsychotic medication in schizophrenia, considering how adherence is defined and measured before considering its predictors, an area that is best understood by considering a health belief model.

Clinical factors related to schizophrenia relapse

Several classes of risk factors have been proved to be relevant in the risk of relapse and a careful assessment of the risk factors here identified should be performed in daily clinical practice in order to individualise the relapse risk for each patient and to provide a targeted treatment in high-risk subjects.

6 Antipsychotic drugs

Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital

In Asian patients with schizophrenia, clozapine was the most effective antipsychotic in terms of time to discontinuation, followed by aripiprazole.

References

SHOWING 1-10 OF 12 REFERENCES

Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Although the acquisition cost of clozapine is high in comparison with that of standard antipsychotics, preliminary cost-effectiveness estimates in patients with treatment-resistant schizophrenia suggest that the clinical benefits of the drug may confer medium to long term economic benefits, primarily by reducing the need for psychiatric hospital services.

Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders

This case series underlines the safety and efficacy of clozapine as add-on medication in the treatment of bipolar and schizoaffective disorders.

Clinical experience with clozapine in Germany

Due to its significant antipsychotic, and to its probable even if mild antidepressive efficacy as well as to its possible efficacy against some negative symptoms of schizophrenia, clozapine is currently a real and indispensable alternative to other existing neuroleptics.

Long‐term clinical and Social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs

  • L. Lindström
  • Psychology, Medicine
    Acta psychiatrica Scandinavica. Supplementum
  • 1994
It is concluded that, in many schizophrenic patients, atypical neuroleptics should be preferred in long‐term maintenance treatment because of a low incidence of extrapyramidal syndromes as well as cognitive and emotional parkinsonism.

Clozapine treatment of schizophrenia.

A 27-year-old woman was admitted to the National Institutes of Health Clinical Center, Bethesda, Md, for inpatient research protocol for schizophrenia, and discontinued antipsychotic drug treatment because of adverse effects on several occasions; in each case, she became acutely psychotic.

Recent advances in the pharmacotherapy of schxzophrenia

It is likely that these novel antipsychotic drugs will displace the typical neuroleptic drugs as the primary treatment of schizophrenia.

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

It is suggested that clozapine therapy significantly reduces suicidal behavior in patients with schizophrenia and schizoaffective disorder at high risk for suicide, and use of clozAPine in this population should lead to a significant reduction in suicidal behavior.

Agranulocytosis during clozapine therapy

Treatment of Suicidality in Schizophrenia

  • H. Meltzer
  • Psychology, Medicine
    Annals of the New York Academy of Sciences
  • 2001
The International Suicide Prevention Trial (InterSePT) is a large prospective, randomized study intended to compare the effectiveness of clozapine with that of olanzapine in reducing suicide and suicide‐related events in schizophrenic and schizoaffective patients.